Generics?????

Generics have been eating our pie of revenue is the buzz following everywhere in Social media by the big players, whether its BMS and Astra, Astra at this point is in pretty bad shape as a giant which BMS was there 10 years back, BMS recovered with strategic partnership and alliances but what about Astra will it be able to cope?

These Big Pharma knew that generics will one or the other day will eat their pie of revenue and the best way to stop them is by making stringent regulations for sales and promotion.......

Astra should have thought beforehand about all this when it was making strategic blunders over the last three years ??????

After the generics and counterfeits ......it’s time for biosimilars to eat the revenue of big players  

Merck-Will this strategy help???

Today one of the top line news is that Merck and company is expanding in HIV arena, by signing two licensing agreements for investigational drug candidates. One deal is with Chimerix, based in Research Triangle Park, NC, and the other is with Yamasa of Choshi, Japan. With respect to its own portfolio Merck is also planning to advance an internally developed HIV candidate, MK-1439, which is into a Phase IIb trial. The question which is bugging my mind is that will Merck be able to penetrate the market which is majorly monopolized by Gilead for more than decade and if it is thinking of penetrating to the emerging markets, then will it be able to displace the stiff competition from companies like Cipla who have been playing the low price game for more than 3 decades? Food for thought ………..